TG THERAPEUTICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 17.96 USD | +3.70% |
|
+4.54% | +5.15% |
| May. 01 | Wall Street Set to Open Lower Ahead of Fed Rate Decision; Private Employment Figures Top Forecasts | MT |
| May. 01 | Transcript : TG Therapeutics, Inc., Q1 2024 Earnings Call, May 01, 2024 |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Hours!
Take advantage of the offer
* See conditions on site
Financials (USD)
| Sales 2024 * | 309M | Sales 2025 * | 472M | Capitalization | 2.48B |
|---|---|---|---|---|---|
| Net income 2024 * | -3M | Net income 2025 * | 101M | EV / Sales 2024 * | 7.79 x |
| Net cash position 2024 * | 75.29M | Net cash position 2025 * | 205M | EV / Sales 2025 * | 4.81 x |
| P/E ratio 2024 * |
-787
x | P/E ratio 2025 * |
26.8
x | Employees | 284 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 90.42% |
More Fundamentals
* Assessed data
More news
Latest transcript on TG Therapeutics, Inc.
More recommendations
More press releases
| 1 day | +3.70% | ||
| 1 week | +4.54% | ||
| Current month | +31.48% | ||
| 1 month | +27.65% | ||
| 3 months | +26.57% | ||
| 6 months | +64.02% | ||
| Current year | +5.15% |
1 week
16.60
18.37
1 month
12.9318.37
Current year
12.8422.67
1 year
6.4631.92
3 years
3.4841.00
5 years
3.4856.74
10 years
3.3256.74
| Managers | Title | Age | Since |
|---|---|---|---|
Michael Weiss
CEO | Chief Executive Officer | 58 | 93-05-17 |
Sean Power
DFI | Director of Finance/CFO | 42 | 11-12-28 |
Jenna A. Bosco
IRC | Investor Relations Contact | - | 11-11-30 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Michael Weiss
CEO | Chief Executive Officer | 58 | 93-05-17 |
Laurence Charney
BRD | Director/Board Member | 76 | 12-02-29 |
Kenneth Hoberman
BRD | Director/Board Member | 59 | 14-12-14 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.08% | 2 M€ | -.--% |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-13 | 17.32 | +4.21% | 4,316,617 |
| 24-05-10 | 16.62 | -1.77% | 2,226,828 |
| 24-05-09 | 16.92 | -1.17% | 2,679,217 |
| 24-05-08 | 17.12 | -0.35% | 4,230,768 |
| 24-05-07 | 17.18 | +4.06% | 4,532,309 |
Delayed Quote Nasdaq, May 14, 2024 at 04:00 pm EDT
More quotes
TG Therapeutics, Inc. is a fully integrated, commercial stage, biopharmaceutical company. The Company is focused on the acquisition, development and commercialization of novel treatments for B-cell diseases. Its clinical drug candidates include Ublituximab (anti-CD20 mAb), TG-1701 (BTK inhibitor) and TG-1801 (anti-CD47/CD19 bispecific mAb). BRIUMVI is an anti-CD20 monoclonal antibody for the treatment of RMS, which include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease. TG-1701 is a novel, orally available and covalently bound Brutonâs tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in in vitro kinase screening. TG-1801 is a bispecific CD47 and CD19 antibody. It is the therapy to target both CD19, a B-cell specific market expressed across B-cell malignancies, and CD47. It also evaluates complementary products, technologies and companies for in-licensing, partnership, acquisition and/or investment opportunities.
Calendar
2024-06-14
- Annual General Meeting
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C-
Sell
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
17.32
USD
Average target price
31.5
USD
Spread / Average Target
+81.87%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +5.15% | 2.48B | |
| +29.03% | 48.16B | |
| -0.10% | 41.73B | |
| +43.45% | 41.03B | |
| -5.26% | 28.77B | |
| +11.48% | 25.59B | |
| -22.74% | 18.96B | |
| +9.06% | 12.92B | |
| +30.01% | 12.03B | |
| -1.51% | 11.77B |
- Stock Market
- Equities
- TGTX Stock